a buffered pvp-i solution of 2.5% concentration can be used for prevention of neonatal conjunctivitis, especially if it is caused by "neisseria gonorrhoeae", or "chlamydia trachomatis". it is currently unclear whether pvp-i is more effective in reducing the number of cases of conjunctivitis in neonates over other methods. pvp-i appears to be very suitable for this purpose because, unlike other substances, it is also efficient against fungi and viruses (including hiv and "herpes simplex").